US 12,091,425 B2
Compounds that inhibit MCL-1 protein
David Karl Bedke, North Attleboro, MA (US); Michael W. Gribble, Jr., Somerville, MA (US); Michael G. Johnson, San Francisco, CA (US); Todd J. Kohn, Thousand Oaks, CA (US); and Kexue Li, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Oct. 14, 2021, as Appl. No. 17/501,075.
Application 17/501,075 is a continuation of application No. 16/078,152, granted, now 11,306,107, previously published as PCT/US2017/019336, filed on Feb. 24, 2017.
Claims priority of provisional application 62/300,013, filed on Feb. 25, 2016.
Prior Publication US 2023/0052348 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 513/10 (2006.01); C07D 513/20 (2006.01); C07D 515/10 (2006.01)
CPC C07D 513/10 (2013.01) [C07D 513/20 (2013.01); C07D 515/10 (2013.01)] 7 Claims
 
1. A compound, wherein the compound has a formula selected from one of the following:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein TBS refers to the t-butyldimethylsilyl group.